Skip to main content
Premium Trial:

Request an Annual Quote

Scynexis Expands ACD Processing Tools Installation

NEW YORK, April 19 (GenomeWeb News) - Scynexis, a drug-discovery and -development company, has expanded its installation of Advanced Chemistry Development's ACD/1D NMR Processor, the companies said today.


The expanded nuclear magnetic resonance processing capabilities have been added to Scynexis' research facility in Research Triangle Park, NC, the companies said.


ACD claims that the tool eases the interpretation of NMR data through multiplet analysis, verification, and quantitation techniques, cutting NMR interpretation and dissemination times.


Financial details were not discussed.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.